Physician profile
Christopher E Beney
NPI 1669492096
$25,964.58
in general payments reported to CMS, 2019-2025
62 companies · $2,697 in 2025
The $2,697 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,619 · 2020: $2,638 · 2021: $3,418 · 2022: $3,257 · 2023: $2,954 · 2024: $3,381 · 2025: $2,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,021 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,021.42 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,014.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,174.67 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $2,710.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,015.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,587.99 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,437.43 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Abbvie INC. | $1,271.45 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $653.09 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $611.22 | 2021-2025 | |
| Amgen INC. | $556.56 | 2019-2024 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $522.01 | 2019-2025 | Trintellix, Glassia |
| Otsuka America Pharmaceutical, INC. | $472.19 | 2020-2025 | Rexulti |
| Corcept Therapeutics | $443.62 | 2024-2025 | Korlym |
| Genzyme Corporation | $358.04 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $352.84 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Beney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.